|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:flurazepam
|
|
gptkbp:approvedBy
|
1970
|
|
gptkbp:ATCCode
|
gptkb:N05CD01
|
|
gptkbp:availableOn
|
capsule
|
|
gptkbp:chemicalFormula
|
gptkb:C21H23ClFN3O
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
sleep apnea syndrome
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:drugClass
|
benzodiazepine
|
|
gptkbp:eliminationHalfLife
|
40-250 hours (active metabolites)
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dalmane
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
opioids
antipsychotics
antidepressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children
elderly
|
|
gptkbp:overdoseSymptoms
|
confusion
coma
somnolence
|
|
gptkbp:overdoseTreatment
|
gptkb:flumazenil
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:riskFactor
|
gptkb:center
cognitive impairment
dependence
withdrawal symptoms
paradoxical reactions
next-day impairment
falls (in elderly)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
drowsiness
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:flurazepam
|
|
gptkbp:bfsLayer
|
7
|